Opigolix

Opigolix
Clinical data
Other names	ASP-1707
Routes of; administration	By mouth
Drug class	GnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
	IUPAC name (2R)-N'-[5-[3-(2,5-difluorophenyl)-2-(1,3-dihydrobenzimidazol-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl]sulfonyl-2-hydroxypropanimidamide;
CAS Number	912587-25-8 ;
PubChem CID	11977994;
UNII	VQ6CK0CITA;
KEGG	D11351;
Chemical and physical data
Formula	C25H19F3N4O5S
Molar mass	544.51 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H](/C(=N/S(=O)(=O)C1=C(C=CC(=C1)C(=O)C(=C2NC3=CC=CC=C3N2)C(=O)C4=C(C=CC(=C4)F)F)F)/N)O;
	InChI InChI=1S/C25H19F3N4O5S/c1-12(33)24(29)32-38(36,37)20-10-13(6-8-17(20)28)22(34)21(23(35)15-11-14(26)7-9-16(15)27)25-30-18-4-2-3-5-19(18)31-25/h2-12,30-31,33H,1H3,(H2,29,32)/t12-/m1/s1; Key:CWNLBPBIFALUQD-GFCCVEGCSA-N;

Opigolix (INN, USAN; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis.[1][2] It was also under investigation for the treatment of prostate cancer.[1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018.[1]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.